Two Sovereign Funds Back Series C in Codiak BioSciences
Posted on 11/30/2017
Codiak BioSciences, Inc., an exosome therapeutics company, raised a US$ 76.5 million Series C round. Exosomes are nanometer-sized membrane sacs, or vesicles, that are released and received by nearly all cells. Codiak’s initial investors, including ARCH Venture Partners, Flagship Pioneering, Fidelity Management and Research Company, the Alaska Permanent Fund Corporation (APFC), and Alexandria Venture Investments, […]
- Alaska Permanent Fund Corporation
- Alternatives
- Codiak BioSciences
- pharmaceuticals
- Qatar Investment Authority
- Venture Capital
